Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

NCT01537432 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis, Plaque-type Psoriasis

Interventions

DRUG: secukinumab
DRUG: placebo

Sponsor

Novartis Pharmaceuticals